TOMI Environmental Solutions, Inc.

Good day, everyone, and welcome to the Tomi Environmental Solutions, Inc. First Quarter 2026 Financial Results Conference Call. At this time, all participants are placed on a listen-only mode. If you have any questions or comments during the presentation, you may press star 1 on your phone to enter the question queue at any time, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to hand the floor over to your host, John Nesbitt of IMS Investor Relations. Sir, the floor is yours.

Thank you for joining us today for the TOME Environmental Solutions Investor Update Conference Call. On today's call is TOME's Chief Executive Officer and Chairman, Dr. Halden Shane, E.J. Shane, our Chief Operating Officer, and our Chief Financial Officer, David Gansman. A telephone replay of today's call will be available through May 15th, the details of which are included in the company's press release. A webcast replay will also be available on TOME's website, www.steramist.com. Certain written and oral statements made by management of TOME may constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements should be evaluated in light of important risk factors that could cause actual results to differ materially from our anticipated results. Information provided in this conference call is based upon the facts and circumstances known at this time. Please refer to our filings with the Securities and Exchange Commission for discussion of these risk factors. The company undertakes no obligation to update these forward-looking statements after the date of this call. I will now turn the call over to Tony's Chief Executive Officer and Chairman of the Board, Dr. Alden Chang. Please go ahead.

Thank you, John, and thank you all for joining us today. Thank you. Q1 2026 marked a healthy start to the year, highlighted by a pivotal strategic development before Tomi. Our first quarter results demonstrated significant momentum across key metrics. Revenue increased by 5% year-over-year and 67% sequentially from Q4 of 2025. Notably, Applicator sales in Q1 alone surpassed our total applicator sales for the entire year of 2025, representing a remarkable 139% year-over-year growth. This success underscores the effectiveness of our razor razor blade consumable model as we expand our installed base. Additionally, BIT Solution sales have consistently grown by 21% annually since 2024 and remained above the 2025 levels in Q1 of 2026. We also achieved a 15% reduction in operating expenses compared to Q1 of 2025 while maintaining our full capacity. The company also generated positive operating cash flow of 296,000, which is a $572,000 improvement over the same period last year. A notable trend this year is strengthening and dynamic nature of our integrated project pipeline, which continues to demonstrate meaningful momentum. This is the pipeline the company has highlighted since November of 2025, and which evolves as we advance or complete contracts. The expansion of this pipeline aligns closely with growth in our backlog, and we are disclosing only opportunities that suppliers have indicated are near signing. These opportunities tend to involve longer sales cycles. While near-term closings are communicated as they firm up, they do not represent our entire potential opportunity. The trend is reflected in our backlog of orders. At year end of 2025, TOME reported 1.6 million in backlog, which grew by half a million by the close of Q1 2026. and is currently at 2.2 million. This steady backlog expansion underscores the strength of our automated integrated system and the many service offerings we implemented. Critically, backlog growth continues even as we fulfill existing orders, illustrating demand and execution across sales. At the end of quarter one, Tomi received 440,000 annual purchase orders for recurring decontamination services with a leading global medical technology company. This contract involves quarterly professional IHP decontamination services for critical cleanroom and laboratory environments, aligning perfectly with our strategy to build a high margin, repeatable revenue model, in addition to increasing the backlog order number. In Q1, we achieved several other notable milestones. A private East Coast research university purchased and installed a scurumous hybrid system for high-level decontamination of reusable medical equipment. We also sold a custom engineered system in the U.K. to an international pharmaceutical manufacturer, which was integrated into Total Clean Air's module clean room platform. And we established Total Clean Air as a preferred European partner for Sterimist IHP technology when the U.K. health and safety executive granted regulatory authorization for a bit solution and Sterimist IHP products. The food safety sector is gaining real traction. We launched an important case study that demonstrated up to 95% reduction in sanitization testing costs for an egg food manufacturer. Our long-standing partner, DisinfectCare, secured a service contract at a major Mexican dairy facility where rigorous testing highlighted stariness IHP's efficacy while preserving product quality. Further, the end user is looking to expand its use of Sturimist IHP in Mexico to its other facilities. There are other positive food safety tests that the company has received to be discussed at a later date. This is all exciting stuff for us. Regulatory advancements have also played a critical role in our progress. In February, we received official authorization from the UK Health and Safety Executive for a BIT solution and Sterimist IHP products for use in Great Britain. and Northern Ireland. In March, we secured product authorization from the Dutch regulatory authority, making our first product approval within an EU member state and facilitating a streamlined recognition pathway across the EU. And this past week, we received notification of further approvals in Germany, Belgium, Denmark, and Hungary. We anticipate many other regulatory wins in the near future. On April 30th, 2026, we executed a non-binding letter of intent to merge with Carbonium Core Incorporated, a US-based producer of nuclear-grade graphite for advanced reactor technologies and AI data center infrastructure. Carbonium Core boosts a vertical integrated production platform and exclusive purification technology developed with Oak Ridge National Laboratory. This merger targets a specialty market currently dominated by foreign supply coinciding with increasing domestic demand for non-Chinese origin graphite due to new U.S. FEOC regulations and federal support for advanced nuclear energy. To be clear, with this transaction, our country will become the leader in Generation 4 nuclear reactors. a class of advanced nuclear systems designed to offer significantly improved safety, efficacy, and sustainability compared to current commercial plants. These reactors are characterized by their ability to operate at a A much higher temperature gas cooled reactor pebble bed module recognizes the world's first operational generation four reactor. These systems aim to overcome limitations of current technology by producing more fuel than they consume and ensuring that severe accidents resulting in radioactive release are physically impossible. Under the terms of the LOI, Corbonian Core would become a wholly owned subsidiary of Tome. Former stockholders would receive Tome common stock equal to 19.99% of shares outstanding prior to the merger, along with shares of a newly created series of convertible preferred stock, implying an enterprise valuation of $120 million. We aim to finalize definitive agreements by May 30th, 2026, with a 45-day exclusivity period in place. The strategic rationale for this transaction is compelling. It aims to diversify TOME's business by merging a domestic platform focused on advanced nuclear-grade graphite, graphene, and lithium materials with our existing stereomist decontamination business. This integration has the potential to unlock significant long-term value for our shareholders while enhancing and expanding the Cerimus brand. Please note that the LOI is non-binding and the completion of the transaction is subject to definitive agreement, due diligence, and customary closing conditions, including stockholder approval. I'll now turn the call over to our Chief Financial Officer, David Vanson, for a review of our Q1 financial results.